DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
MT-1303 is an investigational drug.
There have been 11 clinical trials for MT-1303. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation and [disabled in preview].
There are seven US patents protecting this investigational drug and fifty-four international patents.
Recent Clinical Trials for MT-1303
|Extension Study of MT-1303 in Subjects With Crohn's Disease||Mitsubishi Tanabe Pharma Corporation||Phase 2|
|Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease||Mitsubishi Tanabe Pharma Corporation||Phase 2|
|Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients||Mitsubishi Tanabe Pharma Corporation||Phase 1|
Top disease conditions for MT-1303
Top clinical trial sponsors for MT-1303
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MT-1303||Start Trial||Kinase inhibitors||Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)||Start Trial|
|MT-1303||Start Trial||Kinase inhibitors||Respivert Limited (N/A) Topivert Pharma Limited (London, GB)||Start Trial|
|MT-1303||Start Trial||Sphingosine pathway modulating compounds for the treatment of cancers||Enzo Biochem, Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|